secwatch / observer
8-K filed November 8, 2022, 6:59 PM ET ticker ONCO CIK 0001782107
leadership confidence high sentiment neutral materiality 0.30

Blue Water Vaccines appoints Vuk Jeremić to board; Michael Venerable resigns

Onconetix, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Vuk Jeremić

Director
ONCO · Onconetix, Inc.
Effective
2022-11-04
Filed
November 8, 2022, 6:59 PM ET
Effective as of November 4, 2022, the Board appointed Vuk Jeremić to serve as a member of the Board and a member of the Nominating and Corporate Governance Committee of the Board and Compensation Committee of the Board.
Departed

Michael Venerable

Director
ONCO · Onconetix, Inc.
Effective
2022-11-04
Filed
November 8, 2022, 6:59 PM ET
Effective as of November 4, 2022, Michael Venerable resigned as a member of the Board of Directors (the "Board") of Blue Water Vaccines Inc. (the "Company").

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vuk Jeremić was appointed as Director at Onconetix, Inc..

Action
appointed
Role
Director
Exact text from the filing
Effective as of November 4, 2022, the Board appointed Vuk Jeremić to serve as a member of the Board and a member of the Nominating and Corporate Governance Committee of the Board and Compensation Committee of the Board.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Venerable resigned as Director at Onconetix, Inc..

Action
resigned
Role
Director
Exact text from the filing
Effective as of November 4, 2022, Michael Venerable resigned as a member of the Board of Directors (the "Board") of Blue Water Vaccines Inc. (the "Company").
View on SEC.gov

Onconetix, Inc. filing history →

Source: SEC EDGAR
accession 0001213900-22-069929
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.